It has been reported that phosphorylated paxillin increases Bcl-2 expression through the ERK signaling pathway as the cause of cisplatin resistance in non-small cell lung cancer, and Src or ERK inhibitors help restore the sensitivity of lung cancer patients to cisplatin chemotherapy [180]. This evidence concerns the gene BCL2 and non-small cell lung carcinoma.